Roche lung cancer drug success adds to pressure on Bristol

Lung cancer patients on Roche’s immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb’s dominant position in the field.

The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even in people with low or no levels of a protein called PD-L1, which is often used to test suitability for immunotherapy.

Leave a Reply

Your email address will not be published.

x

Check Also

امیتابھ کی فلم سیٹ پر کھلونا بائیک چلانے کی تصاویر وائرل

امیتابھ کی فلم سیٹ پر کھلونا بائیک چلانے کی تصاویر وائرل

بالی ووڈ کے شہنشاہ امیتابھ بچن نے سیٹ پر کچھ تفریحی لمحات کی ایک جھلک ...

%d bloggers like this: